Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Pediatric NF1 with Plexiform Neurofibromas
NCT00076102Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2004
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in plexiform neurofibroma (PN), sponsored by National Cancer Institute. Primary endpoints: Median Time to Disease Progression at 5 years, Number of Participants With Adverse Events at 5 years and 1 more. Started Jul 2004; status: completed.
02
Drugs
pirfenidone
03
Conditions
plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT00076102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076102.